HUMA Humacyte, Inc. Earnings per share growth rate in current year

Corporate emblem and logo of Humacyte, Inc. (HUMA)

The annual growth rate of net income per share for Humacyte, Inc. (HUMA) reflects the impact of FDA approval expectations and current sales under special programs. The foundation for growth is based on the pricing power of bioengineered vessels and the creation of a unique living tissue ecosystem for surgery. Meanwhile, the -59.70 mark indicates the current trend of this metric, capturing the company's earnings volatility in the present period.

HUMA - Humacyte Inc Earnings growth in current year over the range 07/04/2022 - 11/10/2026

Analytical breakdowns and data insights for company Humacyte, Inc. (HUMA)

- current quotes and average value forecast:
Market Chart Humacyte Inc|HUMA - Price Target Chart
- market capitalization data:
Market Value Humacyte Inc.|HUMA - Total Company Value
- balance sheet equity data:
Equity per Share Humacyte|HUMA - Book Capitalization|Market Value to Book Value humacyte.com|HUMA - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Humacyte, Inc.|HUMA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio humacyte.com|HUMA - Company Aggregate Debts|Debts to Book Capitalization Humacyte Inc.|HUMA - Company Long-Term Debts|Company Current Liabilities Humacyte|Immediate Liquidity humacyte.com
- earnings and market ratios statistics:
HUMA - Net Income|Future Net Profit Humacyte, Inc.|HUMA - P/E Multiple|Projected Price to Earnings Ratio Humacyte Inc.|HUMA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Humacyte Inc.|HUMA - Operating profit EBITDA|Net earnings per share for the last four quarters Humacyte|HUMA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months humacyte.com|HUMA - Earnings growth in current year|Expected earnings per share growth for next year Humacyte, Inc.
Fundamental valuation:Humacyte, Inc.
Manufactured product of Humacyte

The dynamics of this metric reflect operational efficiency through the percentage change in net income per share compared to the same period last year. By analyzing the chart of annual EPS growth, an investor assesses the monetization of Humacyte, Inc. (HUMA) bioengineered tissues in cardiology and traumatology, where success in a narrow high-tech niche directly determines the pace of profit scaling and the fundamental value of the business.

Direct competitors

NTRA - Expected net earnings per share growth this year|Earnings per share growth in current year Sera Prognostics